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To clarify the optimal cumulative cisplatin dose (CCD) in locoregionally-advanced
nasopharyngel carcinoma (NPC) patients receiving induction chemotherapy (IC) plus
concurrent chemoradiotherapy (CCRT). Using the NPC-specific database from the
established big-data intelligence platform at Sun Yat-Sen University Cancer Center,
583 non-disseminated, locoregionally-advanced NPC patients receiving IC plus
CCRT were enrolled. Propensity score matching (PSM) analysis was conducted to
control for confounding factors. The median CCD was 160 mg/m2 after IC (range,
40-300 mg/m2); only 74 patients (12.7%) achieved CCD >200 mg/m2. Patients
receiving >200 mg/m2 CCD did not show significantly improved 5-year overall
survival (OS) (HR = 1.19; 95% confidence intervals [CI] 0.69-2.06, P = .53) and
progression-free survival (PFS) (HR = 1.03; 95% CI: 0.63-1.68, P = .92) compared
with patients receiving <200 mg/m2 CCD. Further investigations of the potential of
median CCD (160 mg/m2) to yield survival benefits revealed that there were no sig-
nificant differences in survival endpoints between patients receiving CCD >160 mg/
m2 and CCD < 160 mg/m2 in both the original and PSM cohorts. In addition, sub-
group analysis indicated a favorable PFS, but not OS, with higher cisplatin adminis-
tration in patients with pretreatment Epstein–Barr virus deoxyribonucleic acid (EBV
DNA) <1000 copies/mL (HR = 0.26, 95% CI: 0.07-0.93, P = .03) and receiving <3 IC
cycles (HR = 0.59, 95% CI 0.33-1.07, P = .08). Our analysis of real world data pro-
vided references for the optimal CCD in locoregionally-advanced NPC receiving
additional IC. The causal relationship between 200 mg/m2 CCD and improved sur-
vival was not defined; 160 mg/m2 CCD might be enough. However, for patients
with EBV DNA <1000 copy/mL and receiving <3 IC cycles, a higher dose might be
necessary.
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1 | INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer
with skewed epidemiology, pathology and response to treatment.1
The highest incidence worldwide is reported among the Cantonese
population of Guangdong Province, where rates ranged from 22.2 to
27.2 per 100 000 males and 9.8 to 11.1 per 100 000 females.2
Radiotherapy (RT) is the primary treatment modality for non-dis-
seminated NPC due to its radiosensitivity and anatomical location.
NPC is also known to be chemosensitive. The integration of cis-
platin-based chemotherapy during RT greatly enhances the effects
of RT, facilitates local control and improves therapeutic outcomes.3,4
Recently, adding induction chemotherapy (IC) before concurrent
chemoradiotherapy (CCRT) has been found to greatly improve sur-
vival outcomes, and has been increasingly adopted worldwide based
on the clinical data from several important large-scale multi-centre
phase II-III randomized controlled trials (RCT), which strongly support
the application of IC plus CCRT for locoregionally-advanced NPC.5-9
The cumulative cisplatin dose (CCD) administered during RT is
an important factor in conferring survival benefits. In the majority
of RCTs, 100 mg/m2 cisplatin was administered every 3 weeks
during RT. The importance of a third planned cisplatin cycle was
first questioned by Ang et al,10 who reviewed the compliance
levels of CCRT in RCT, and found that a substantial fraction of
patients failed to receive the third cycle, and a cumulative dose
of 200 mg/m2 was sufficient to yield beneficial antitumor effects.
Peng et al. also demonstrated that CCD >240 mg/m2 was not
prognostic in patients with locoregionally-advanced NPC, and that
200 mg/m2 cisplatin may be adequate.11 Furthermore, Loong and
colleagues found that 200 mg/m2 CCD had prognostic value in
patients with stage II and III NPC, but not in patients with the
highest risk.12
Accordingly, 200 mg/m2 has been widely used as the optimal
cutoff value in clinical practice, regardless of the specific treatment
strategies. However, patients enrolled in the studies on which this
value is based all received CCRT and a subpopulation did not receive
intensity-modulated radiotherapy (IMRT). Moreover, several factors
require consideration regarding patients receiving IC plus CCRT in
the era of IMRT. First, IC greatly reduced tumor volume burden.
Clinical complete response (cCR) and partial response (cPR) were
observed in 11.3% and 79.6% of patients, respectively.13 Second,
patients may be less able to tolerate the subsequent highly intensive
CCRT after 2-4 cycles of IC. Data from published RCT showed that
36% of patients could not adhere to the second planned cisplatin,
and that 76.7% of patients could not achieve the third.5 Third, IMRT
is superior in the management of local control compared to conven-
tional RT.14,15 Given these facts and the current lack of data, the
suitability of 200 mg/m2 CCD as the optimal cutoff value for locore-
gionally-advanced NPC patients receiving IC plus CCRT in the era of
IMRT remains to be elucidated.
Real world data (RWD) are increasingly used to guide clinical
practice and assist in the the assessment of the “value” of the inter-
vention, as they are characterized by variety, veracity and are
unfiltered compared with RCT data, which can be confounded by
the selection of the patient population, rigorous administration and
physician preferences.16,17 Therefore, RWD represent an important
resource in research, and are promising in answering this question.
Using an NPC population from an endemic area, we aimed to clarify
the optimal CCD in locoregionally-advanced NPC patients receiving
IC plus CCRT.
2 | MATERIALS AND METHODS
2.1 | Patient population and data extraction
The NPC-specific database from the well-established big-data intelli-
gence platform at Sun Yat-Sen University Cancer Centre (SYSUCC)
was adopted to identify 2940 patients with histologically-proven,
non-disseminated NPC, diagnosed between January 2005 and
December 2012. A detailed description of this database is presented
in the Appendix S1. Using the search terms “diagnosis,” “histology
type,” “stage classification,” “radiotherapy” and “chemotherapy,” we
identified patients fulfilling the following inclusion criteria: (i) patient
diagnosed as histologically-proven non-keratinising NPC; (ii) disease
classified as stages III-IVb; (iii) patient received IC plus CCRT; (iv)
received 2-4 cycles of IC; (v) received cisplatin-based concurrent
chemotherapy (weekly or 3-weekly); and (vi) radiation delivery tech-
nique was IMRT. Finally, 583 eligible patients were enrolled in our
analysis. The detailed selection process and study design are pre-
sented in Figure 1. This study was approved by the Clinical Research
Ethics Committee of SYSUCC. The authenticity of this article has
been validated by uploading the key raw data onto the Research
Data Deposit (RDD) public platform (http://www.researchdata.org.c
n), with the approval RDD number as RDDA2017000364.
2.2 | Chemotherapy
The concurrent chemotherapy consisted of 40 mg/m2 cisplatin
administered every week for a maximum of 7 cycles, 80 mg/m2 cis-
platin administered every 3 weeks for a maximum of 3 cycles, or
100 mg/m2 cisplatin administered every 3 weeks for a maximum of
3 cycles, beginning on the first day of RT or 3 weeks after the last
cycle of IC.
The IC regimens included docetaxel/cisplatin/fluorouracil (TPF),
docetaxel/cisplatin (TP), cisplatin/fluorouracil (PF), gemcitabine/cis-
platin (GP) and others. Details of the dose and algorithm for dose
adjustment in IC and CCRT are presented in the Appendix S1.
2.3 | Radiotherapy
All patients were treated with radical IMRT comprising 5 daily frac-
tions delivered each week for 6-7 weeks. The prescribed doses were
66-72 Gy at 2.12-2.43 Gy/fraction to the planning target volume
(PTV) of the primary gross tumor volume (GTVnx), 64-70 Gy/28-
33 fractions to the PTV of the GTV of the involved lymph nodes
(GTVnd), 60-63 Gy/28-33 fractions to the PTV of the high-risk
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F IGURE 1 Flowchart showing the
study design and patient selection process
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clinical target volume (CTV1) and 54-56 Gy/28-33 fractions to the
PTV of the low-risk clinical target volume (CTV2).
2.4 | Clinical staging, follow up and study endpoint
All patients were restaged according to the 8th edition of the UICC/
AJCC staging system.18 Patients were followed up from the initiation
of the treatment to the day of last examination or death. Details of
the pretreatment examinations and follow-up strategies are shown
in the Supplementary materials (Appendix S1).
The primary endpoint was overall survival (OS), which was calcu-
lated from the date of treatment initiation to death from any cause.
The secondary endpoint was progression-free survival (PFS), defined
as the time from treatment initiation to tumor progression or death;
distant metastasis-free survival (DMFS) was defined as the time to
tumor metastasis; and locoregional relapse-free survival (LRFS) was
the time to the first locoregional relapse.
2.5 | Study design and statistical analysis
At the time this study was conducted, no data regarding the optimal
CCD administered during RT for NPC patients receiving IC plus
CCRT were available; however, published data suggested that a CCD
of 200 mg/m2, irrespective of the schedule, was necessary to confer
benefit among patients treated with CCRT alone.11,12 Therefore,
CCD of 200 mg/m2 was used as the cutoff value in the first step of
this study. We found that CCD of 200 mg/m2 was not able to con-
fer survival benefit in locoregionally-advanced NPC patients receiv-
ing IC plus CCRT. Next, we identified the median CCD after IC as
160 mg/m2 in this cohort. Thus, we hypothesized that 160 mg/m2
CCD might be sufficient to yield beneficial antitumor effects. Fur-
thermore, we noted differences between 2 groups in terms of fac-
tors including age, tumor stage (T stage), node stage (N stage),
disease stage, pretreatment Epstein–Barr virus deoxyribonucleic acid
load (EBV DNA), IC regimens and IC cycles. To control for possible
confounding factors and to minimize bias with respect to initial
treatment selection, 2 well-balanced cohorts were generated through
propensity score matching (PSM) analysis in the third step of the
study,19 during which patients without complete data regarding EBV
DNA were excluded (n = 111). Finally, subgroup analyses were con-
ducted in the PSM cohort to identify the subgroups that might ben-
efit most from the administration of higher doses of cisplatin after
IC (Figure 1).
Propensity scores were calculated based on logistic regression
for the following 8 variables: age, sex, year of diagnosis, T stage, N
stage, pretreatment EBV DNA, IC cycles and IC regimens. Patients
were matched without replacement at a 1:1 ratio using estimated
propensity scores. The patient and tumor characteristics between
groups were compared using the v2-test (Fisher’s exact test or Pear-
son’s v2-test where appropriate) for categorical variables and the
Kruskal-Wallis test for continuous variables. Kaplan-Meier survival
analysis was used to estimate the actuarial survival rates and log-
rank tests were used for comparisons. The unadjusted Cox
proportional hazards model was used to calculate the hazard ratio
(HR) in the subgroup analysis. The adjusted HR was calculated using
the Cox regression mode, for the 8 factors (age, sex, year of diagno-
sis, T stage, N stage, pretreatment EBV DNA, IC cycles and IC regi-
mens). The proportional hazards assumption was graphically verified
on the basis of Schoenfeld residuals.20 All analyses were performed
using SPSS version 22.0 (SPSS, Chicago, IL, USA) and STATA version
12.0 (Stata Corporation, USA). Two-sided P < .05 was considered to
indicate statistical significance.
3 | RESULTS
3.1 | Patient characteristics and treatment
compliance
The baseline characteristics of 583 eligible patients were presented
in Table 1. The median age at diagnosis was 44 years (range, 18-
76 years); 48.5% of subjects were at stage III (n = 283) and 51.5%
were at stage IV (n = 300). In total, 55.9% of patients (n = 326)
received 2 cycles of IC, and 44.1% (n = 257) received 3-4 cycles.
TPF was the most commonly used IC regimen (41.7%; n = 243). For
70.3% of the patients (n = 410), cisplatin was administered every
3 weeks during RT and 29.7% of the patients (n = 173) received
weekly administration of cisplatin.
The median CCD for the whole cohort was 160 mg/m2 (range,
40-300 mg/m2). In total, 325 patients (55.7%) received CCD
>160 mg/m2, and 258 (44.3%) received CCD <160 mg/m2, while
509 patients (87.3%) received CCD <200 mg/m2 and only 74 pa-
tients (12.7%) received CCD >200 mg/m2.
During the median follow-up of 62.0 months (range, 3.3-
85.6 months), 102 patients (17.5%) died, 102 patients (17.5%) devel-
oped distant metastases and 56 patients (9.6%) developed locore-
gional recurrence (34 patients had local recurrence, and 31 patients
had regional recurrence). The 5-year OS, PFS, DMFS and LRFS val-
ues were 82.8%, 75.4%, 82.1% and 90.2%, respectively.
3.2 | Identification of the optimal cumulative
cisplatin dose during radiotherapy in locoregionally-
advanced nasopharyngel carcinoma patients receiving
induction chemotherapy plus concurrent
chemoradiotherapy
Previously publsihed data suggested that 200 mg/m2 CCD was nec-
essary to confer survival benefit among patients receiving CCRT
alone. Therefore, we first investigated the potential of 200 mg/m2
CCD in achieving survival benefit in locoregionally-advanced NPC
patients treated with IC plus CCRT. Kaplan-Meier survival analysis
indicated that there was no significant improvement in the prognosis
of patients receiving CCD > 200 mg/m2 in terms of 5-year OS
(HR = 1.19; 95% confidence intervals [CI], 0.69-2.06, P = .53), PFS
(HR = 1.03; 95% CI: 0.63-1.68, P = .92), DMFS (HR = 1.22; 95% CI:
0.70-2.10, P = .49) and LRFS (HR = 0.84; 95% CI: 0.36-1.96,
P = .68; Figure 2).
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Having identified the median cisplatin dose after IC as 160 mg/
m2 in the whole cohort, we then hypothesized that 160 mg/m2 CCD
might be sufficient to yield beneficial effects. Kaplan-Meier survival
analysis demonstrated that there were no statistically significant dif-
ferences between patients receiving CCD > 160 mg/m2 and patients
receiving CCD <160 mg/m2 in terms of 5-year OS (HR = 1.02; 95%
CI: 0.69-1.50, P = .94), PFS (HR = 0.97; 95% CI: 0.70-1.35, P = .85),
DMFS (HR = 1.04; 95% CI: 0.70-1.54, P = .85) and LRFS
(HR = 1.00; 95% CI: 0.59-1.69, P = .99; Figure 3).
3.3 | Clinical implications of 160 mg/m2 cumulative
cisplatin dose in the propensity score matched cohort
We then verified the role of 160 mg/m2 CCD in the propensity
score matched cohort to minimize bias in the initial treatment selec-
tion. After PSM, all covariates were well-balanced between the
groups (Table 2). In a univariate analysis, no significant survival dif-
ferences were observed between groups in terms of 5-year OS
(HR = 0.81; 95% CI: 0.48-1.35, P = .41), PFS (HR = 0.89; 95% CI:
0.57-1.38, P = .59), DMFS (HR = 0.91; 95% CI: 0.56-1.49, P = .71)
and LRFS (HR = 0.73; 95% CI: 0.36-1.48, P = .38; Figure 4).
Multivariate analysis was performed to adjust for potential prog-
nostic confounders, including IC cycles, IC regimens, age, sex, year
of diagnosis, T category, N category and pretreatment EBV DNA. In
accordance with the previous results, 160 mg/m2 CCD was not
identified as an independent prognostic factor for locoregionally-
advanced NPC patients receiving IC plus CCRT in terms of 5-year
OS (HR = 0.75; 95% CI: 0.44-1.27, P = .28), PFS (HR = 0.86; 95%
CI: 0.55-1.33, P = .49), DMFS (HR = 0.90; 95% CI: 0.54-1.47,
P = .66) and LRFS (HR = 0.69; 95% CI: 0.34-1.42, P = .31). Table 3
shows all other variables associated with survival endpoints.
3.4 | Subgroup analysis
Subgroup analyses were further conducted for OS and PFS, to identify
the subgroups that might benefit from the administration of higher cis-
platin dose after IC. We found that there were no interactions
between clinicopathologic variables and 160 mg/m2 CCD with respect
to OS (Figure 5A). However, interactions of 160 mg/m2 CCD with
pretreatment EBV DNA and IC cycles were observed with respect to
PFS (Pinteraction = 0.04; Figure 5B). In the subgroup of patients with
pretreatment EBV DNA <1000 copies/mL, administration of
CCD > 160 mg/m2 tended to yield favorable prognosis (HR = 0.26;
95% CI: 0.07-0.93, P = .03), while the survival benefit was not
observed in patients with pretreatment EBV DNA > 1000 copies/mL
(HR = 1.12; 95% CI: 0.69-1.82, P = .64). In addition, there was poten-
tially greater benefit for the subgroup of patients who received
TABLE 1 Basic characteristics of patients with nasopharyngeal










(n = 258) P-valuea
Sex
Male 443 (76.0) 246 (75.7) 197 (76.4) .85
Female 140 (24.0) 79 (24.3) 61 (23.6)
Age (years)
<45 306 (52.5) 183 (56.3) 123 (47.7) .02
46-65 260 (44.6) 137 (42.2) 123 (47.7)
>66 17 (2.9) 5 (1.5) 12 (4.7)
Year of diagnosis
2005-2010 224 (38.4) 114 (35.1) 110 (42.6) .06
2011-2013 359 (61.6) 211 (64.9) 148 (57.4)
T categoryb
T1 25 (4.3) 16 (4.9) 9 (3.5) .01
T2 46 (7.9) 22 (6.8) 24 (9.3)
T3 317 (54.4) 161 (49.5) 156 (60.5)
T4 195 (33.4) 126 (38.8) 69 (26.7)
N categoryb
N0 42 (7.2) 20 (6.2) 22 (8.5) .22
N1 289 (49.6) 170 (52.3) 119 (46.1)
N2 116 (19.9) 57 (17.5) 59 (22.9)
N3 136 (23.3) 78 (24.0) 58 (22.5)
Stage categoryb
III 283 (48.5) 139 (42.8) 144 (58.5) <.01




112 (19.2) 57 (17.5) 55 (21.3) .21
≥1000
copies/mL
360 (61.7) 211 (64.9) 149 (57.8)
Unkown 111 (19.0) 57 (17.5) 54 (20.9)
IC cycles
2 cycles 326 (55.9) 164 (50.5) 162 (62.8)
3 cycles 218 (37.4) 153 (47.1) 65 (25.2)
4 cycles 39 (6.7) 8 (2.5) 31 (12.0)
IC regimens
TPF 243 (41.7) 165 (50.8) 78 (30.2) <.01
TP 185 (31.7) 84 (25.8) 101 (39.1)
PF 142 (24.4) 71 (21.8) 71 (27.5)
Othersc 13 (2.2) 5 (1.5) 8 (3.1)
CCRT regimens
Weekly DDP 173 (29.7) 47 (14.5) 126 (48.8) <.01
3-weekly
DDP
410 (70.3) 278 (85.5) 132 (51.2)
CCD, cumulative cisplatin dose; CCRT, concurrent chemotherapy; DDP,
cisplatin; EBV DNA, Epstein–Barr virus deoxyribonucleic acid; IC,
induction chemotherapy; N, node; T, tumor.
aTwo-sided P-values were calculated using the v2-test or Fisher’s exact
test if indicated.
bAccording to the 8th edition of the American Joint Committee on Cancer.
cOthers included gemcitabine plus cisplatin (GP) or patients with regimen
alterations during the IC.
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2 cycles of IC with the higher dose of cisplatin administration
(CCD > 160 mg/m2) after IC (HR = 0.59; 95% CI: 0.33-1.07, P = .08);
however, this benefit was not observed in patients receiving more
than 2 cycles of IC (HR = 1.50; 95% CI: 0.76-2.96, P = .24).
4 | DISCUSSION
It is generally recognized that 200 mg/m2 CCD administered dur-
ing RT is the optimal cutoff dose to yield survival benefit in NPC
patients receiving CCRT.11,12,21 However, with the success of sev-
eral important large-scale multi-centre phase II-III RCT, an increas-
ing number of patients are receiving IC plus CCRT; and a
substantial proportion of patients are unable to tolerate 200 mg/
m2 CCD following IC, due to the increased therapeutic intensity.
This has led to debate over the suitability of 200 mg/m2 as the
optimal cutoff CCD in these circumstances. To the best of our
knowledge, this was the first real world investigation of the opti-
mal cutoff CCD for locoregionally-advanced NPC patients receiving
IC plus CCRT in the era of IMRT.
F IGURE 2 Kaplan-Meier survival analyses of: A, overall survival, B, progression-free survival, C, distant metastasis-free survival and D,
locoregional relapse-free survival, in locoregionally-advanced NPC patients receiving IC plus CCRT, stratified by CCD >200 mg/m2 and CCD
<200 mg/m2. CCD, cumulative cisplatin dose; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; NPC, nasopharyngeal carcinoma
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Our data indicate that there was no significant survival improve-
ment in patients receiving >200 mg/m2 CCD compared with those
receiving <200 mg/m2 CCD. In the whole cohort, the median CCD
was 160 mg/m2 after IC. Further investigations of the potential of a
CCD of 160 mg/m2 to yield survival benefits revealed that there
were no significant differences between patients receiving
CCD > 160 mg/m2 and those receiving CCD < 160 mg/m2 in rela-
tion to all survival endpoints both in the original and PSM cohorts.
In addition, subgroup analysis demonstrated potentially favorable
PFS, but not OS, in patients with pretreatment EBV
DNA < 1000 copies/mL, and <3 cycles of IC with higher cisplatin
administration.
In the present study, 200 mg/m2 CCD did not yield significant
improvements in survival outcomes in patients with locoregionally-
advanced NPC receiving IC plus CCRT, while 160 mg/m2 CCD
might be enough to yield beneficial antitumor effects. This is in
accordance with previously published reports.11,12,21 In the com-
bined analyses of 2 prospective trials, NPC-9901 and NPC-
9902,21 a total dose of cisplatin during the concurrent phase
(>200 mg/m2) had a significant impact on LRFS and OS in the
F IGURE 3 Kaplan-Meier survival analyses of: A, overall survival, B, progression-free survival, C, distant metastasis-free survival and D,
locoregional relapse-free survival, in locoregionally-advanced NPC patients receiving IC plus CCRT, stratified by CCD >160 mg/m2 and CCD
<160 mg/m2. CD, cumulative cisplatin dose; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; NPC, nasopharyngeal
carcinoma
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stage III subgroup, but not in the stage IV subgroup. Loong and
colleagues12 also found that CCD > 200 mg/m2 had prognostic
value in patients with stage II and III NPC, but not in patients
with stage IV disease. It can be speculated that this divergence in
the results is because the patients enrolled in the previous studies
received CCRT, and a substantial number of the patients did not
receive IMRT. In contrast, all the patients included in the present
study received IC plus CCRT, and the radiotherapy modality was
consistently IMRT. The rationale for the decreased CCD was
based on the reduced tumor volume after IC,7,13 impaired medica-
tion adherence after intensive IC,5 increased survival outcomes by
adding IC before CCRT6,7 and significant advances in RT delivery
techniques (such as IMRT).22,23 The cCR plus pCR rates have been
reported to reach 90% after IC;13 therefore, the subsequent
administration of less intensive chemotherapy during RT is feasi-
ble.
Although a positive relationship between higher CCD and
improved survival outcomes was not observed in the whole
cohort, further subgroup analyses indicated that patients with pre-
treatment EBV DNA of <1000 copies/mL and receiving <3 cycles
of IC benefit from a higher dose of cisplatin after IC. The rela-
tionship between pretreatment EBV DNA and CCD is an area of
TABLE 2 Comparison of basic characteristics in the entire cohort and propensity-score matched cohort
Characteristics
Entire cohort Propensity-score matched cohort
CCD >160 mg/m2
(n = 325), %
CCD <160 mg/m2
(n = 258), % P-valuea
CCD >160 mg/m2
(n = 180), %
CCD <160 mg/m2
(n = 180), % P-valuea
Sex
Male 246 (75.7) 197 (76.4) .85 133 (73.9) 134 (74.4) .90
Female 79 (24.3) 61 (23.6) 47 (26.1) 46 (25.6)
Age (years)
<45 183 (56.3) 123 (47.7) .04 78 (43.3) 86 (47.8) .40
≥45 142 (43.7) 135 (52.3) 102 (56.7) 94 (52.2)
Year of diagnosis
2005-2010 114 (35.1) 110 (42.6) .06 58 (32.2) 54 (30.0) .65
2011-2013 211 (64.9) 148 (57.4) 122 (67.8) 126 (70.0)
T categoryb
T1-2 38 (11.7) 33 (12.8) .69 26 (14.4) 20 (11.1) .34
T3-4 287 (88.3) 225 (87.2) 154 (85.6) 160 (88.9)
N categoryb
N0–1 190 (58.5) 141 (54.7) .36 96 (53.3) 93 (51.7) .75
N2–3 135 (41.5) 117 (45.3) 84 (46.7) 87 (48.3)
Stage categoryb
III 139 (42.8) 144 (58.5) <.01 80 (44.4) 91 (50.6) .25
IV 186 (57.2) 114 (44.2) 100 (55.6) 89 (49.4)
Pretreatment EBV DNA
<1000 copies/mL 57 (17.5) 55 (21.3) .21 40 (22.2) 40 (22.2) 1.00
≥1000 copies/mL 211 (64.9) 149 (57.8) 140 (77.8) 140 (77.8)
Unkown 57 (17.5) 54 (20.9) — —
IC cycles
2 cycles 164 (50.5) 162 (62.8) <.01 104 (57.8) 97 (53.9) .46
> 2 cycles 161 (49.5) 96 (37.2) 76 (42.2) 83 (46.1)
IC regimen
TPF 165 (50.8) 78 (30.2) <.01 62 (34.4) 69 (38.3) .44
TP+PF+othersc 160 (49.2) 180 (69.8) 118 (65.6) 111 (61.7)
CCD, cumulative cisplatin dose; CCRT, concurrent chemotherapy; DDP, cisplatin; EBV DNA, Epstein–Barr virus deoxyribonucleic acid; IC, induction
chemotherapy; N, node; NPC, nasopharyngeal carcinoma; T, tumor.
aTwo-sided P-values were calculated using the v2-test or Fisher’s exact test if indicated.
bAccording to the 8th edition of the American Joint Committee on Cancer.
cOthers included gemcitabine plus cisplatin (GP), or patients with regimen alterations during the IC. The following variables were used for propensity-
score matching: age (≥45 vs <45 years), sex (female vs male), year of diagnosis (2011-2013 vs 2005-2010); tumor category (T 3–4 vs T 1–2); node cate-
gory (N2–3 vs N0–1); pretreatment EBV DNA (≥1000 copies/mL vs <1000 copies/mL); IC cycles (>2 cycles vs 2 cycles); IC regimen (TPF vs all others).
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particular interest. It has been well documented that pretreatment
EBV DNA is a robust factor in the diagnosis, risk stratification
and relapse prediction of NPC.24-26 Patients with higher pretreat-
ment EBV DNA loads were positively correlated with higher
tumor burden, and associated with impaired prognosis. In this
study, the subgroup with lower pretreatment EBV DNA was
shown to benefit from higher cisplatin administration. It can be
speculated that this effect is associated with the inherently poor
prognosis of locoregionally-advanced NPC patients with high
tumor burden (EBV DNA >1000 copies/mL), irrespective of the
concurrent cisplatin dose. This finding is in accordance with the
reports of Lee et al21 and Loong et al12 that CCD had prognostic
value in patients with lower risk (stage III), but not in patients
with the highest risk (stage IV).
In addition to the influence of pretreatment EBV DNA, IC
cycles also modified the prognostic effect of CCD. Previous stud-
ies showed that there was no difference in survival between
patients receiving 2 cycles of IC and patients receiving >2 cycles
of IC, when the CCRT regimens and cycles were well-balanced
between groups.27 Our results shed light on the previous findings
F IGURE 4 Kaplan-Meier survival analyses of: A, overall survival, B, progression-free survival, C, distant metastasis-free survival, and D,
locoregional relapse-free survival, in the propensity score matched cohort, stratified by CCD >160 mg/m2 and CCD <160 mg/m2. CCD,
cumulative cisplatin dose; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; NPC, nasopharyngeal carcinoma
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that for patients received less than 3 cycles of IC, higher CCD
(> 160 mg/m2) during CCRT might be necessary to yield the same
antitumor effects.
Although there was an association between CCD and PFS in
subgroups of patients with pretreatment EBV DNA <1000 copies/
mL and receiving <3 cycles of IC, the prognostic effect was not
observed in terms of OS. This could be explained by the failure of
the study to demonstrate a statistical difference; thus, longer follow-
up time and/or larger sample sizes are needed to validate our find-
ings in future prospective studies.
The aim of concurrent chemotherapy is to yield beneficial antitu-
mor effects with acceptable toxicities. With a broad standard appli-
cation of IC and the increased therapeutic intensity, a substantial
proportion of patients are unable to tolerate 200 mg/m2 CCD. Thus,
it is crucial to define the optimal cutoff dose that can confer survival
advantage, with the minimal and acceptable toxicities under these
circumstances. Although the current study provides the basis of a
hypothesis, further confirmatory prospective studies are required to
guide changes in clinical practice. Nevertheless, our results provide a
reference for the determination of optimal CCD in clinical practice,
and reduce the requirement for rigorous application of the total dose
of 200 mg/m2 cisplatin in CCRT, when patient performance status is
significantly decreased after IC. Furthermore, based on our findings,
we recommend that 160 mg/m2 CCD should be considered as a ref-
erence cisplatin dose in future clinical trials of IC plus CCRT in
locoregionally-advanced NPC.
The strengths of the present study are that we enrolled a real
world population, which included patients with both good and rela-
tively poor performance status, and reflected the true conditions of
concurrent chemotherapy after IC. Conceivably, patients in poor
health are less likely to tolerate toxic treatments such as concurrent
chemotherapy; and highly intensive treatment might lead to health
deterioration and, consequently, to impaired survival. However, the
strict inclusion criteria and rigorous administration of clinical trials
could have biased the enrolment towards younger and healthier
patients; in addition, participants are encouraged to follow up the
predefined protocols. Second, compared with other retrospective
studies, in which data were collected manually, data in the present
study were stored and extracted from the established NPC-specific
database affiliated to the big-data intelligence platform in our cancer
center. This enabled the patient population, treatment schemes and
follow-up schedules to be more consistent and reliable. Third, we
carefully designed the methodology to control for confounding fac-
tors through PSM, which facilitated the provision of consistent and
high-quality data.
Nevertheless, several limitations of the present study should be
stated. First, as with all retrospective analyses of patients treated at
a single centre, survival outcomes may have been confounded by
various undefined factors. Large-scale, multi-institutional, prospective
studies are warranted to further confirm our findings. Second, the
efficacy of different IC regimens could have confounded the survival
outcomes. However, to date, there is no evidence to indicate the
superior IC regimen, and all regimens included in this study were
TABLE 3 Cox proportional hazards analyses of prognostic factors
for the propensity-score matched cohort
Endpoint Variable HR 95% CI P-valuea







N (N3–4 vs N1–2) 2.31 1.30-4.08 <.01
IC regimens
PF Reference
TPF 0.41 0.20-0.81 .01
TP 0.49 0.26-0.94 .03
Others 0.52 0.07-4.01 .53
PFS CCD (>160 mg/m2
vs < 160 mg/m2)
0.86 0.55-1.33 .49
N (N3-4 vs N1-2) 1.99 1.23-3.36 <.01
IC regimens
PF Reference
TPF 0.57 0.31-1.04 .06
TP 0.48 0.28-0.85 .01
Others 0.99 0.29-3.36 .98







N (N3–4 vs N1–2) 3.20 1.80-5.68 <.01
IC regimens
PF Reference
TPF 0.56 0.28-1.10 .09
TP 0.56 0.30-1.05 .06
Others 1.43 0.41-5.02 .58
LRFS CCD (>160 mg/m2
vs < 160 mg/m2)
0.69 0.34-1.42 .31
T category 4.67 0.60-36.13 .09
IC regimens
PF Reference
TPF 0.48 0.19-1.24 .13
TP 0.44 0.18-1.06 .06
Others 0.00 — .98
CI, confidence interval; DMFS, distant metastasis-free survival; HR, haz-
ard ratio; radiotherapy; LRFS, locoregional relapse-free survival; NS, not
significant; OS, overall survival; PFS, progression-free survival.
aThe following parameters were included in the Cox proportional hazards
model multivariate analysis: cumulative cisplatin dose (CCD > 160 mg/
m2 vs CCD < 160 mg/m2); IC cycles (>2 cycles vs 2 cycles); IC regimens
(TPF vs TP vs PF vs others); age (>66 vs 45-65 vs <45 years); sex (fe-
male vs male); year of diagnosis (2011-2013 vs 2005-2010); tumor cate-
gory (T3–4 vs T1–2); node category (N2–3 vs N0–1) and pretreatment
Epstein–Barr virus DNA (≥1000 copies/mL vs <1000 copies/mL).
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F IGURE 5 Prognostic effects of 160 mg/m2 CCD on: A, overall survival, and B, progression-free survival, stratified by patient and
treatment characteristics in subgroups. CCD, cumulative cisplatin dose
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platinum-based; moreover, the propensity-matched analysis was
applied to create well-balanced groups and to reduce the bias.
In conclusion, the causal relationship between 200 mg/m2 CCD
and improvement in survival outcomes was not defined in locore-
gionally-advanced NPC patients receiving IC plus CCRT, and our
results indicated that 160 mg/m2 CCD might be sufficient to yield
beneficial antitumor effects in IC. However, higher doses of cisplatin
delivered during RT are required to achieve beneficial effects in
patients with pretreatment EBV DNA <1000 copies/mL and receiv-
ing <3 cycles of IC.
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